Table 1 Patient demographics
From: Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice
N = 60 | % | |
|---|---|---|
Mean age | 65.9 | |
Range | 45–84 | |
Gender | ||
Male | 29 | 48.3 |
Female | 31 | 51.7 |
Smoking history | ||
Current smoker | 44 | 73.3 |
Past smoker | 16 | 26.7 |
ECOG PS | ||
0 | 5 | 8.3 |
1 | 15 | 25 |
2 | 20 | 33.3 |
3 | 19 | 31.7 |
4 | 1 | 1.7 |
Stage | ||
LD | 33 | 55 |
ED | 27 | 45 |
Histology | ||
Small cell carcinoma | 59 | 98.3 |
Combined small cell carcinoma | 1 | 1.7 |
Treatment | ||
Chemotherapy | 51 | 85 |
Refused | 3 | 5 |
Not fit | 3 | 5 |
RT/surgery | 3 | 5 |
First-line chemotherapy | ||
Carbo/etoposide | 13 | 21.7 |
ACE | 13 | 21.7 |
MVP | 13 | 21.7 |
Etoposide | 5 | 8.3 |
Cisplatin/etoposide | 2 | 3.3 |
Other/no chemotherapy | 5/9 | 8.3/15 |
Number of cycles of treatment | ||
1–3 cycles | 16 | 31.4 |
4–6 cycles | 35 | 68.6 |
Response to first-line treatment | ||
Complete response | 4 | 7.8 |
Partial response | 29 | 56.9 |
Stable disease | 10 | 19.6 |
Progressive disease | 8 | 15.7 |